Virtual CME Program
4.00 CME/CE Credit
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of opioid abuse. Pri-Med’s P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-25 curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.
Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
CME/CE Information
4.00 AMA PRA Category 1 Credits™, 4.00 ABIM MOC or 4.00 AANP, including 1.38 AANP Pharm
Release Date: 8/27/2025
Expiration Date: 8/27/2025
Topics
Learning Objectives
- Discuss the definitions and mechanisms of pain
- Identify risk factors and stratification for opioid-related aberrant behavior and opioid use disorder as part of the initial assessment
- Apply individualized recommendations for nonpharmacologic and non-opioid treatment options for patients in pain
- Review general characteristics of opioid analgesics including their intended use and risks
- Differentiate among tolerance, physical dependence, and manifestations of opioid use disorder
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal
- Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone
- Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain
- Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate
- Summarize counseling strategies for caregivers and patients on opioid therapy
- Act appropriately to evaluate, treat, or refer patients with opioid use disorder
Faculty
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine, Senior Vice-Chair, School of Medicine and Biomedical Sciences, University of Buffalo School of Medicine
Chief, Division of Pain Medicine, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
Learn More
Aubrey J. Grant, MD, FACC
Founder and CEO, Equity Commons
Sports Cardiologist, MedStar Health and Georgetown University
Team Cardiologist, Baltimore Ravens, Baltimore Orioles, Washington Capitals
Member, Diversity and Inclusion Committee,, American College of Cardiology
Learn More
Charles E. Argoff, MD, FABPM
Vice Chair, Albany Medical College, Professor of Neurology and Urology
Director, Comprehensive Pain Center, Albany Medical Center, Director, Pain Management Fellowship, Albany, New York
Learn MoreDisclosures
The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute
Charles E. Argoff, MD, FABPM: Speaker: AbbVie, Averitas Pharma, Impel, Kowa Pharmaceuticals, Lilly, Lundbeck, Nevro, Scilex, Teva
Researcher: AbbVie; Consultant: Collegium, Nevro, Pain Scripts, Scilex, Tris, Vertex, Xgene Pharma; Stockholder: Pfizer and Trevana;
Investigator: Lundbeck and Teva.
Oscar A. de Leon-Casasola, MD: Consultant for Merck and Vertex
Katherine E. Galluzzi, DO, CMD, FACOFP: Advisory Board for Eli Lilly
All others in control of content for this activity have disclosed no relevant financial relationships
CME/CE Information
AMA PRA Category 1 Credits™
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Equity Commons and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this live activity for a maximum of 4.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Equity Commons and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.
Designation Statement
This activity is approved for 4.00 contact hour of continuing education, which includes 1.38 hours of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Supported by
Opioid Analgesic REMS Program CompaniesEducation Partner
Miller Medical Communications, LLCFine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.